• linkedin
  • Increase Font
  • Sharebar

    PCa immunotherapy: Response better when given before ADT


    “As both our biomarker and imaging knowledge advances, it is important to interrogate additional markers, which can be used as appropriate surrogates for clinical and therapeutic decision-making for patients with high-risk disease—albeit whom are earlier in their disease stage. Thus, the immunologic parameters we chose have been widely utilized in other trials for evidence of response and effectiveness,” he said.

    Also see - RCC: Multiple pathways provide therapeutic targets

    In the study, patients received either sipuleucel-T followed by androgen deprivation therapy or the reverse sequence. PA2024-specific Enzyme-Linked ImmunoSPOT responses were similar between groups, except at week six, when responses were higher in the group receiving the immunotherapy prior to androgen deprivation therapy. Men in both arms showed increased PA2024-specific cellular and humoral responses, and prostatic acid phosphatase-specific humoral responses, which remained higher than baseline for 2 years. Average time-to-PSA recurrence also was similar in both groups.

    Sipuleucel-T has become an important part of guideline recommendations in the treatment of men with metastatic castrate-resistant prostate cancer. The National Comprehensive Cancer Network has given sipuleucel-T its highest level of recommendation for specific metastatic castrate-resistant prostate cancer patients. The AUA includes it in its recommendations for castrate-resistant prostate cancer. And on Dec. 21, the Society for Immunotherapy of Cancer published the first evidence-based consensus statement guiding physicians on the use of cancer immunotherapy to treat prostate cancer.

    Dr. Shore has research and consulting ties with AbbVie, Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Medivation, Moivant, Sanofi-Genzyme, and Tolmar.

    More on Targeted Therapy:

    Immunotherapies move toward FDA approval for urothelial Ca

    Next-gen sequencing panel for renal Ca earns CLIA approval

    Oral agent improves survival in advanced RCC patients

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available